Trevi Therapeutics, Inc.
TRVI· Nasdaq
Released Aug 13, 2020, after the close
10-Q filed Aug 13, 2020, 44 days after period end · 0001564590-20-040031
| Metric | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|
| Net Income | -$7.38M | -$7.35M | -$4.86M |
| EPS Diluted | -$0.41 | -$0.63 | -$13.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Trevi Therapeutics, Inc. · CIK 1563880 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end
7.4% from the close of Aug 13, 2020 to the close of Aug 17, 2020, the first after the release.